U.S. Patent Trial and Appeal Board Cancels all claims in United Therapeutics’ ‘393 patent for purification of prostacyclin derivatives, rendering patent invalid. SteadyMed plans to file New Drug Application (NDA) for Trevyent® for the treatment of Pulmonary Arterial Hypertension (PAH) in Q2 2017 SAN RAMON, Calif., March 31, 2017 (GLOBE NEWSWIRE) — SteadyMed Ltd. (Nasdaq:STDY), ...
The post SteadyMed Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent appeared first on ForexTV.
March 31, 2017 at 11:44PM
http://ift.tt/2oqids6
from Nasdaq NewsFeed
http://ift.tt/2oqids6
No comments:
Post a Comment